Skin Toxicities Compromise Prolonged Pemetrexed Treatment
Open Access
- 1 December 2011
- journal article
- research article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 6 (12), 2083-2089
- https://doi.org/10.1097/jto.0b013e31822e722f
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Pemetrexed-induced edema of the eyelidLung Cancer, 2010
- Pemetrexed-Induced Fluid RetentionJournal of Thoracic Oncology, 2010
- Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 studyThe Lancet, 2009
- Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancerBMC Cancer, 2008
- Pemetrexed-induced edema of the eyelidLung Cancer, 2006
- Pemetrexed, a Novel Antifolate Therapeutic Alternative for Cancer ChemotherapyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2006
- FDA Drug Approval Summaries: Pemetrexed (Alimta®)The Oncologist, 2004
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004
- Pemetrexed safety and dosing strategySeminars in Oncology, 2002
- Phase II trial of pemetrexed disodium (ALIMTA®, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancerAnnals of Oncology, 2002